The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Imfinzi also recommended for patients with mismatch repair deficient disease
Subscribe To Our Newsletter & Stay Updated
